Pentosan Polysulfate Sodium (PPS) is used to treat interstitial cystitis. Its long-term use may be associated with the development of a maculopathy.
Clinical features:
(1) therapy with pentosan polysulfate sodium, often long-term, with risk related to total dose received
(2) variable loss of visual acuity
(3) difficulty reading
(4) difficulty with dark adaptation
(5) blurred vision
(6) metamorphopsia
(7) development of a pigmentary maculopathy with hyper- and hypoautofluorescent spots
Risk of developing the maculopathy (Vora et al):
(1) cumulative dose 500 to 999 grams: odds ratio 1.0
(2) cumulative dose 1,000 to 1,500 grams: odds ratio 2.95
(3) cumulative dose > 1,500 grams: 4.91
